Congenital deficiency of C1 inhibitor, the main inhibitor of the classic complement system pathway, leads to paroxysmal angioedema (hereditary angioedema) that can be debilitating or life-threatening for affected patients. In the past few years many new insights on the pathogenesis of angioedema formation in the presence of low levels of C1 inhibitor has been accumulated. There is a central role for bradykinin that is released upon activation of the kallikrein-kinin system that is insufficiently controlled by adequate levels of C1 inhibitor. As C1 inhibitor also possesses a central regulatory role of other plasma systems, including the contact activation system of coagulation and the plasminogen-plasmin system that governs endogenous fibrinolysis, it is interesting to observe the effects of C1 inhibitor deficiency on activation of these systems and relevance for hemostasis in vivo and thrombo-embolic disease. Interestingly, and despite significant activation of these pathways, C1 inhibitor deficiency is not at all associated with a hemorrhagic tendency or prothrombotic state. New therapeutic options for treatment of C1 inhibitor efficiency have become available in recent years, including various forms of C1 inhibitor concentrate. Restoration of C1 inhibitor levels in patients with hereditary angioedema has not resulted in thrombotic complications or any other relevant disorder associated with the hemostatic system.
| INTRODUCTION
Hereditary angioedema (HAE) is a condition caused by deficiency of C1 inhibitor, in most cases as a dominant autosomal disorder although about one third of cases represent spontaneous genetic mutations in the Serpin-1 gene. Affected patients present with paroxysmal localized swellings due to extravasation of fluid from the circulation into the extracellular space. In the past few decades it has become increasingly clear why deficiency of C1 inhibitor leads to angioedema with a central role of activation of the kallikrein-kinin system and related activity of the contact activation pathway of coagulation. Since C1 inhibitor occupies a central regulatory role in both systems, hereditary angioedema may provide useful insights in the physiological and pathophysiological roles the kallikrein-kinin and contact activation pathways play in hemostasis and thrombosis in vivo. This article reviews the current insights in the lessons we can learn from complement and related system activation regarding their relevance for hemostasis and thrombosis.
| CLINICAL MANIFESTATION OF HEREDITARY ANGIOEDEMA
Hereditary angioedema is manifested by recurrent and episodic swelling affecting any tissue in the human body, most frequently the facial area (including cheeks, eyelid, lips, or tongue), upper airways, upper or lower limbs, genital area, or intestinal and mesenterial structures. Attacks usually have a relatively slow onset (hours) and may be preceded by prodromal symptoms including erythema marginatum, muscle pain or itching. 1 Swelling located at the pharyngeal and laryngeal area is the most serious clinical manifestation as this may lead to airway obstruction and even asphyxia. Laryngeal complications have been reported in more than 20% of patients, sometimes leading to the requirement of tracheal intubation or even emergency tracheotomy. 1 In a retrospective study in the era before adequate treatment of the disease was universally introduced, 40% of patients with hereditary angioedema died from asphyxia. 2, 3 Another dreaded manifestation of angioedema is swelling in the intestinal area leading to severe abdominal pain, nausea, vomiting, and diarrhea. Abdominal angioedema attacks may closely mimic acute abdominal diseases such as appendicitis and in the past patients often underwent unnecessary surgical intervention due to improper diagnosis. However, with modern imaging (eg, abdominal CT scan) distended intestinal bowel loops with extensive swelling in combination with free fluid in the abdomen and pelvis detected has greatly facilitated the diagnosis. 4 In 15% to 30% of patients multiple localizations may occur simultaneously. 5 In a descriptive study of consecutive angioedema attacks in patients with hereditary angioedema 46%, 33%, and 6% of the attacks were related to the limbs, the intestinal tract, and upper airways, respectively. 6 In another series, 95% of hereditary angioedema patients suffered from skin manifestations, 60% from facial swelling, and 96% from abdominal attacks. 1 Symptomatic systemic hypotension most probably due to abdominal fluid displacement is another frequently reported symptom in 9% of patients. Although patterns of angioedema attacks can be quite consistent in a single patient, this may not predict the severity and location of a subsequent episode of swelling. 7, 8 Untreated angioedema attacks are self-limiting and usually last for 1-4 days. However, with modern treatment, relief of swelling and complete resolution may occur much more rapidly (see section 5).
Nevertheless, recurrent angioedema attacks are associated with significant reduction in the quality of life and substantial physical and social disability. Although the attacks are reversible and treatable the recurrent character of the symptoms leads to a significant limitation of daily activities and to an increased rate of absence of work and school of both patients and their families. compared to the non-affected extremity. 11, 12 In general, in patients suffering from an angioedema attack enhanced plasma levels of (Lys-) bradykinin are detectable in comparison to levels in between attacks. Blocking the bradykinin receptor-2 abolishes the vaso-active effects of bradykinin and abrogates angioedema. 13 In addition, mice with C1-inhibitor deficiency suffer from increased vascular permeability which is not present if the bradykinin receptor-2 is knocked out as well.
14 Kallikrein can also be generated as a result of prolylcarboxypeptidase (PRCP) activation of plasma prekallikrein ( Figure 1 ). 15 The potential role of this pathway in angioedema is, however, unclear.
| LINKING COMPLEMENT ACTIVATION TO ACTIVATION OF COAGULATION AND FIBRINOLYSIS
As C1 inhibitor is an important regulator of the contact phase system of coagulation and partly of the downstream intrinsic pathway, it may be that a deficiency of this protease inhibitor might affect the hemostatic system. A revised role of the contact system of coagulation has attracted a lot of attention in recent years. Briefly, contact-activated "intrinsic" coagulation appears not to be a physiologic generator of thrombin in vivo. Deficiencies of contact system proteases are not associated with an enhanced bleeding tendency. 16 However, in pathologic states (such as in sepsis) contact system activation may lead to factor XI activation and contribute to downstream thrombin generation, indicating that the contact system is a pathophysiologic generator of thrombin. In addition, contact protein deficiencies seem to protect from thrombosis risk and-inverselyactivation of the contact system in experimental models can lead to pathologic thrombosis. 15, 17, 18 During an angioedema attack in patients with hereditary angioedema there is abundant contact system activation detectable. Plasma levels of cleaved high molecular weight kininogen, and complexes between activated contact system components and C1 inhibitor are significantly higher in this situation as compared to normal. 19, 20 Some studies showed increased factor XIIa levels during an angioedema attack, however, other observations demonstrated that factor XII levels did not change during this situation. [21] [22] [23] The activation of the contact system is associated with increased levels of prothrombin activation fragment F1+2, however, it is not clear whether that is a direct effect of intrinsic pathway activation. 21 Indeed, as factor VIIa levels are increased as well, it may well be that thrombin generation is a consequence of tissue factor-factor VIIa activation. The increase in factor VIIa activity may be a consequence of endothelial cell perturbation during an angioedema attack or as a result of the lack of inhibition of factor VII activating protease (FSAP) due to the C1 inhibitor deficiency. 24 An alternative explanation may be that there is some thrombin generation due to (secondary) factor XII activation in this situation. Recent studies on thrombin formation
with thrombin generation assays demonstrate that the extent of thrombin generation during an angioedema attack is very mild and self-limiting. 25 In addition, C1 inhibitor is an effective inhibitor of plasmin and it is estimated that during activation of fibrinolysis about 15% of plasmin is inhibited by C1-inhibitor in vivo. 26 Hence deficiency of C1 inhibitor can impair the ability to regulate plasmin activity.
Also, C1 inhibitor deficiency leads to increased plasma kallikrein activity, which may directly activate plasminogen into plasmin or indirectly mediate plasminogen activation by activating urokinasetype plasminogen activator or via factor XIIa generation. An additional mechanism may be that insufficiently inhibited FSAP (see above) can also cause urokinase-mediated plasminogen activation. 27 Plasmin itself may generate further factor XII activation and can thereby cause a potentiation of bradykinin generation and angioedema. Indeed, factor XII deficient patients showed a reduced contact activation-dependent activation of endogenous fibrinolysis in vivo. Interestingly, and despite significant activation of the contact activation/intrinsic pathway of coagulation as well as the endogenous fibrinolytic system, C1 inhibitor deficiency is not associated with a hemorrhagic tendency or prothrombotic state. 
| TREATMENT OF C1 INHIBITOR DEFICIENCY AND CONSEQUENCES FOR HEMOSTASIS AND THROMBOSIS
Management of hereditary angioedema is aimed at reducing the severity and duration of an angioedema attack. In addition, strategies to prevent angioedema attacks (either in high risk situations for angioedema formation, such as intra-oral surgery or endotracheal intubation) or in a long-term setting are available as well. 7, 31 Attenuated androgens, such as danazol and stanozol, can be used for prophylaxis of angioedema attacks. Androgens have been demonstrated to increase mRNA expression of C1 inhibitor and since hereditary angioedema is a heterozygous disease, upregulation of the healthy gene may result in higher levels of C1 inhibitor. 33 Besides, attenuated androgens promote bradykinin degradation through an increase in aminopeptidase P. 34 The ability of attenuated androgens to reduce the frequency and severity of angioedema attacks was shown in randomized controlled studies decades ago. 35, 36 Attenuated androgens may cause changes in lipid profiles but have not been associated with atherosclerosis or thrombotic complications. 37 Tranexamic acid (see above) has been shown to be effective in the prevention and treatment of angioedema attacks, although not in all cases. It can often be used for long-term prophylaxis in children, in whom androgens are contraindicated. 7, 8 Although tranexamic acid is an inhibitor of fibrinolysis, its chronic use in patients with hereditary angioedema is not known to cause thrombotic complications. 38 The current most rational approach for prevention and treatment is the administration of C1 inhibitor concentrate. Plasmaderived C1 inhibitor concentrate is available in many countries since the 1970s and was shown to be effective in raising C1 inhibitor plasma levels and reducing angioedema attacks. [39] [40] [41] [42] To achieve licensing in the US, recently two placebo-controlled randomized controlled trials confirmed the efficacy of this therapy.
Nanofiltered plasma-derived C1 inhibitor concentrate decreased the time to the onset of relief from an angioedema attack from more than 4 hours in the placebo group to 2 hours in the treatment group. 43 Likewise, the International Multicenter Prospective Angioedema C1-Inhibitor Trial (IMPACT) showed that another plasma-derived C1 inhibitor concentrate significantly reduced the time to the onset of symptom relief dose-dependently from 90 minutes to 30 minutes in the C1 inhibitor concentrate group at a dose of 20 U/kg C1-inhibitor concentrate and from 90 minutes to 72 minutes at a dose of 10 U/kg, respectively. 44 Prophylactic administration of C1-inhibitor was demonstrated to be effective in a placebo-controlled cross-over study in which the frequency of angioedema attacks was significantly reduced from 12.7 in the placebo group to 6.3 over 12 weeks in the group treated with 1000 U C1 inhibitor concentrate twice a week. 43 Intravenous self-administration of C1 inhibitor concentrate was shown to be effective in markedly reducing time to initiation of treatment and a significantly reduced time to relief and total resolution of angioedema symptoms. 45, 46 A recent trial demonstrated the feasibility of subcutaneous administration of C1 inhibitor concentrate, thereby further facilitating its use for patients. 47 An alternative to plasma-derived C1 inhibitor concentrate is a recombinant concentrate, purified from milk of transgenic rabbits expressing the human C1 inhibitor gene. The major difference between this agent and the plasma-derived product is the much shorter halflife of about 2 hours (probably due to differences in glycosylation). 48 Nevertheless, recombinant C1 inhibitor was effective in both treating acute angioedema attacks and (more surprisingly) in a prophylactic setting to a similar extent as the plasma-derived agent. 49, 50 In Subcutaneous administration of icatibant was shown to be superior to placebo in initiating symptom relief (2.5 hours compared to 4.5 hours in the control group) and was demonstrated to have some modest benefit compared to tranexamic acid in a subsequent randomized controlled trial. 55, 56 It should be mentioned that the comparison between icatibant and tranexamic acid is slightly difficult as tranexamic acid can be used both as an agent that is used in case of an angioedema attack as well as a prophylactic agent whereas icatibant is used for acute angioedema attacks only. The most important side-effect of icatibant is local skin irritation but this compound has not been associated with thrombotic complications.
Very recently, inhibition of other components of the contact activation system (such as plasma kallikrein and factor XIIa) has been focus of new drug development. Lanadelumab is a humanized monoclonal antibody that inhibits plasma kallikrein. 57 In a recent phase III trial subcutaneous administration of lanadelumab significantly reduced HAE attacks in comparison with placebo.
Based on these results, lanadelumab is now (pre-) approved in the US, EU, Canada, Australia, and Switzerland for prevention of HAE attacks in patients aged ≥12 years. In addition, BCX7353, an oral small-molecule inhibitor of plasma kallikrein was evaluated in a phase II dose-escalation trial in 77 patients. 58 The rate of angioedema attacks was significantly lower among patients who received BCX7353 at daily doses of 125 mg or more than among those who received placebo. The most important reported adverse events were mild gastrointestinal complaints. Although no relevant increases risks of bleeding or thrombosis have been reported in the available preclinical and clinical studies with kallikrein inhibitors, 57 ,58 the net effect on hemostasis in vivo and thrombosis remains to be elucidated. 
| CONCLUSION
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